Key result
Aliskiren improves BP control rates by ~53% versus ramipril with noninferior systolic reductions.
Why the study?
Does aliskiren monotherapy improve blood pressure reduction compared to ramipril in patients with stage 2 systolic hypertension?
Population
175 patients with stage 2 systolic hypertension (baseline mean sitting systolic BP [msSBP] ≥160 mmHg)
Comparison
Aliskiren 150 mg monotherapy with optional… vs Ramipril 5 mg monotherapy with optional…
Design
RCT, randomized, double-blind
Follow-up
12 weeks
Authors
Loading...
Supports aliskiren over ramipril for BP control in stage 2 systolic hypertension; extends direct renin inhibition evidence versus ACEI.
RCT (n=175)
double-blind
randomized
Does aliskiren monotherapy improve blood pressure reduction compared to ramipril in patients with stage 2 systolic hypertension?
Absolute Event Rate: 38.6% vs 25.3%
p-value: p=0.038
Aliskiren monotherapy provides effective blood pressure reduction and may be superior to ramipril for diastolic blood pressure control in patients with stage 2 systolic hypertension.
Andersen et al. (2010) conducted an RCT in Stage 2 systolic hypertension (n=175). Aliskiren vs. Ramipril 5 mg with optional up-titration to 10 mg was evaluated on BP control (<140/90 mmHg) (p=0.038). Aliskiren monotherapy was superior to ramipril in achieving blood pressure control (38.6% vs 25.3%; P=0.038) and noninferior for systolic blood pressure reduction (P<0.0001 for noninferiority).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: